Journal
ONCOTARGETS AND THERAPY
Volume 8, Issue -, Pages 783-787Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S78911
Keywords
epidermal growth factor receptor tyrosine kinase inhibitor; MET amplification; epithelial-to-mesenchymal transition
Categories
Funding
- Takeda Pharm Ltd.
- Mochida Pharm Ltd.
- Novartis Pharm Ltd.
- Pfizer Ltd.
- MSD Ltd
- Astellas Pharm Ltd.
- Japan Boehringer-Ingelheim Ltd.
- Daiichi-Sankyo Ltd.
- Dainihon-Sumitomo Pharm Ltd.
Ask authors/readers for more resources
EGFR mutant lung cancer responds to EGFR tyrosine kinase inhibitors (TKIs), but all patients eventually develop resistance to EGFR-TKIs. Herein we report a case of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-TKI with MET amplification and epithelial-to-mesenchymal transition (EMT). A 73-year-old woman was diagnosed with adenocarcinoma harboring an EGFR exon 19 deletion. She received gefitinib as second-line therapy. Tumors were reduced 1 month after gefitinib therapy. However, only a few months later, chest computed tomography results indicated cancer progression. Gefitinib therapy was stopped and docetaxel therapy started. However, she died 13 days after admission. Microscopic examination of postmortem specimens revealed a diffuse proliferation of atypical giant cells in primary and metastatic lesions, but no adenocarcinomatous components as in the antemortem specimens. Immunohistochemical analyses showed that antemortem tumor specimens were positive for CDH1 but negative for VIM. In contrast, postmortem tumor specimens were positive for VIM but negative for CDH1. Genetic analyses revealed MET amplification. We concluded that resistance to EGFR-TKI might be caused by MET amplification and EMT. To our knowledge, no clinical studies have reported that MET amplification and EMT together may be associated with acquired resistance to EGFR-TKI. Second biopsy after the development of EGFR-TKI resistance may be recommended to determine the best therapeutic strategy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available